<!DOCTYPE html>
<html lang="he-IL" dir="rtl">

<head>
  <!-- Meta -->
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta name="description" content="Brilinta">
  <title>Brilinta</title>

  <!-- Font -->
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Poppins:wght@400;500;700&display=swap" rel="stylesheet">

  <!-- Style (Vendor) -->
  <link rel="stylesheet" href="css/swiper-bundle.min.css">

  <!-- Style -->
  <link rel="stylesheet" href="css/elevate-framework.css">
  <link rel="stylesheet" href="css/style.css">

  <!-- Favicon -->
  <link rel="icon" href="img/favicon.png">
</head>

<body class="post-page">

  <!-- Header -->
  <header class="header">
    <div class="container">
      <!-- Logo -->
      <div class="header-logo">
        <a href="#"><img src="img/global/logo.jpg" alt="brilinta-img"></a>
      </div>
      <!-- Hamburger -->
      <div class="header-hamburger d-mobile">
        <a href="#"><img src="img/icons/hamburger.svg" alt="brilinta-img"></a>
      </div>
      <!-- Menu -->
      <div class="header-menu">
        <!-- Links -->
        <div class="header-links">
          <ul class="f-d-16 f-m-30">
            <!-- Item -->
            <li>
              <a href="#">Prescrebing Information</a>
            </li>
            <!-- Item -->
            <li>
              <a href="#">Mechanism of Action</a>
            </li>
            <!-- Item -->
            <li>
              <!-- Accordion -->
              <div class="accordion">
                <!-- Collapsible -->
                <div class="collapsible">
                  <!-- Toggler -->
                  <div class="collapse-toggler">
                    Select Differences to other P2Y12i
                    <img src="img/icons/chevron-down.svg" alt="brilinta-img">
                  </div>
                  <!-- Collapse -->
                  <div class="collapse">
                    <div>
                      <p class="f-m-25"><a href="#">GUIDELINES</a></p>
                      <p class="f-m-25"><a href="#">NATIONAL HEALTH BASKET</a></p>
                      <p class="f-m-25"><a href="#">UP TO DATE LECTURES</a></p>
                    </div>
                  </div>
                </div>
              </div>
            </li>
            <!-- Item -->
            <li>
              <a href="#">Patient Broshure</a>
            </li>
          </ul>
        </div>
        <!-- Search -->
        <div class="header-search">
          <a href="#">
            <img src="img/icons/search-purple.svg" alt="brilinta-img">
          </a>
        </div>
      </div>
    </div>
  </header>

  <!-- Banner -->
  <div class="banner">
    <div class="text text-left">
      <h1 class="f-d-30 f-m-40 regular">
        In patients with ACS, BRILINTA
        <br>demonstrated superior CV events*
        <br>reduction at 12 months in PLATO
      </h1>
    </div>
    <div class="img">
      <picture>
        <source media="(min-width:1024px)" srcset="img/post/banner.jpg">
        <img src="img/post/banner-mobile.jpg" alt="banner-img">
      </picture>
    </div>
  </div>

  <!-- Category Top-->
  <div class="category">
    <div class="top bg-orange" dir="ltr">
      <div class="container">
        <div class="swiper">
          <div class="swiper-wrapper">
            <!-- Slide -->
            <div class="swiper-slide">
              <div>
                <a href="#" class="f-d-16 f-m-25">
                  Clinical trials
                </a>
              </div>
            </div>
            <!-- Slide -->
            <div class="swiper-slide">
              <div>
                <a href="#" class="f-d-16 f-m-25">
                  Efficacy
                </a>
              </div>
            </div>
            <!-- Slide -->
            <div class="swiper-slide">
              <div>
                <a href="#" class="f-d-16 f-m-25">
                  Safety
                </a>
              </div>
            </div>
            <!-- Slide -->
            <div class="swiper-slide">
              <div>
                <a href="#" class="f-d-16 f-m-25">
                  Guidelines
                </a>
              </div>
            </div>
            <!-- Slide -->
            <div class="swiper-slide">
              <div>
                <a href="#" class="f-d-16 f-m-25">
                  Frequent Asked Questions
                </a>
              </div>
            </div>
            <!-- Slide -->
            <div class="swiper-slide">
              <div>
                <a href="#" class="f-d-16 f-m-25">
                  National Health Basket inclusion creteria
                </a>
              </div>
            </div>
          </div>
        </div>
        <div class="swiper-arrows d-mobile">
          <div class="prev"><img src="img/icons/chevron-left-white.svg" alt="brilinta-img"></div>
          <div class="next"><img src="img/icons/chevron-right-white.svg" alt="brilinta-img"></div>
        </div>
      </div>
    </div>

  </div>

  <!-- Post Body -->
  <div class="post-body">
    <div class="container">
      <h2 class="f-d-22 f-m-34">Efficacy</h2>
      <p class="f-d-16 f-m-30">
        Lorem ipsum consectetur adipiscing elit. Vivamus ullamcorper nulla ut dolor commodo tincidunt. Donec cursus,
        libero eu pretium scelerisque, sapien lorem convallis ex, in accumsan odio ligula non nisl. Vestibulum convallis
        gravida mattis. Maecenas et semper tortor. Vivamus varius imperdiet porttitor. Fusce rutrum sit amet lacus id
        condimentum. Etiam ac imperdiet elit, a imperdiet felis. In non fringilla metus. Nunc ac mollis risus.
        <br><br>
        Suspendisse ornare nibh non egestas suscipit. Praesent dictum volutpat ipsum eu bibendum. Donec bibendum arcu
        sed odio cursus viverra quis vitae erat. Vivamus laoreet quam ligula, quis pharetra dolor cursus a. Sed bibendum
        odio vitae lobortis rutrum. Quisque mollis varius est quis porttitor. Fusce finibus dolor vitae porttitor
        interdum. Nam et neque eget sem eleifend condimentum id non leo. Sed blandit, nibh sit amet vehicula dignissim,
        tellus elit interdum ante, at finibus nisl sapien id nisi. Etiam sit amet venenatis neque.
        <br><br>
        Nam rhoncus velit nulla, sit amet tristique odio sollicitudin id. Donec aliquam hendrerit molestie. Nam
        hendrerit leo ligula, at convallis lectus finibus eget. Sed commodo lobortis nibh, in posuere nunc scelerisque
        ullamcorper. Nam blandit consequat vulputate. Nunc odio nisl, dapibus a urna eget, blandit sodales eros. Vivamus
        sodales dolor eget mauris iaculis, id luctus lacus efficitur. Aenean arcu elit, accumsan nec egestas vel,
        faucibus quis sapien. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
        Aliquam maximus tortor sit amet turpis cursus, et accumsan nibh blandit.
      </p>
      <div class="post-img">
        <img src="img/post/img-1.jpg" alt="brilinta-img">
      </div>
      <h3 class="f-d-22 f-m-34">Plato Efficacy End Points​</h3>
      <p class="f-d-16 f-m-30">
        consectetur adipiscing elit. Vivamus ullamcorper nulla ut dolor commodo tincidunt. Donec cursus, libero eu
        pretium scelerisque, sapien lorem convallis ex, in accumsan odio ligula non nisl. Vestibulum convallis gravida
        mattis. Maecenas et semper tortor. Vivamus varius imperdiet porttitor. Fusce rutrum sit amet lacus id
        condimentum. Etiam ac imperdiet elit, a imperdiet felis. In non fringilla metus. Nunc ac mollis risus.
      </p>
      <div class="post-img">
        <img src="img/post/img-2.jpg" alt="brilinta-img">
      </div>
      <p class="f-d-16 f-m-30">
        Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus ullamcorper nulla ut dolor commodo tincidunt.
        Donec cursus, libero eu pretium scelerisque, sapien lorem convallis ex, in accumsan odio ligula non nisl.
        Vestibulum convallis gravida mattis. Maecenas et semper tortor. Vivamus varius imperdiet porttitor. Fusce rutrum
        sit amet lacus id condimentum. Etiam ac imperdiet elit, a imperdiet felis. In non fringilla metus. Nunc ac
        mollis risus.
        <br><br>
        Suspendisse ornare nibh non egestas suscipit. Praesent dictum volutpat ipsum eu bibendum. Donec bibendum arcu
        sed odio cursus viverra quis vitae erat. Vivamus laoreet quam ligula, quis pharetra dolor cursus a. Sed bibendum
        odio vitae lobortis rutrum. Quisque mollis varius est quis porttitor. Fusce finibus dolor vitae porttitor
        interdum. Nam et neque eget sem eleifend condimentum id non leo. Sed blandit, nibh sit amet vehicula dignissim,
        tellus elit interdum ante, at finibus nisl sapien id nisi. Etiam sit amet venenatis neque.
        <br><br>
        Nam rhoncus velit nulla, sit amet tristique odio sollicitudin id. Donec aliquam hendrerit molestie. Nam
        hendrerit leo ligula, at convallis lectus finibus eget. Sed commodo lobortis nibh, in posuere nunc scelerisque
        ullamcorper. Nam blandit consequat vulputate. Nunc odio nisl, dapibus a urna eget, blandit sodales eros. Vivamus
        sodales dolor eget mauris iaculis, id luctus lacus efficitur. Aenean arcu elit, accumsan nec egestas vel,
        faucibus quis sapien. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
        Aliquam maximus tortor sit amet turpis cursus, et accumsan nibh blandit. Suspendisse ut erat nisi. Etiam posuere
        ipsum sed bibendum fermentum. Sed vitae felis et ante lobortis
      </p>
      <div class="post-iframe">
        <div class="ratio-16-9">
          <iframe width="560" height="315" src="https://www.youtube.com/embed/oL6JxSE-Z4E" title="YouTube video player"
            frameborder="0"
            allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture"
            allowfullscreen></iframe>
        </div>
      </div>
      <div class="post-circles">
        <ul>
          <!-- Item -->
          <li>
            <img src="img/post/post-circle-1.jpg" alt="brilinta-img">
            <h3 class="f-d-14 f-m-30 semi-bold">ADHESION</h3>
            <p class="f-d-14 f-m-30">
              Plaque rupture signals nearby platelets to adhere to the injury site. Adhesion triggers platelet
              activation.
            </p>
          </li>
          <!-- Item -->
          <li>
            <img src="img/post/post-circle-2.jpg" alt="brilinta-img">
            <h3 class="f-d-14 f-m-30 semi-bold">ACTIVATION</h3>
            <p class="f-d-14 f-m-30">
              Activated platelets change
              shape and express recptors that
              release the potent platelet agonist ADP,
              leading to initial thrombus formation.
            </p>
            <p class="f-d-14 f-m-30 text-orange">BRILINTA PREVENTS ADP FROM BINDING</p>
          </li>
          <!-- Item -->
          <li>
            <img src="img/post/post-circle-3.jpg" alt="brilinta-img">
            <h3 class="f-d-14 f-m-30 semi-bold">AGGREGATION</h3>
            <p class="f-d-14 f-m-30">
              Activated platelets aggregate at the active lesion site, leading to growth of thrombus.
            </p>
          </li>
        </ul>
      </div>
      <!-- Table 1 -->
      <div class="post-table post-table-1">
        <table class="f-d-16 f-m-28">
          <thead>
            <tr>
              <td>Dyspnea in the PLATO trial</td>
              <td>BRILINTA (n=9235)</td>
              <td>Clopidogrel (n=9186)</td>
              <td>p value</td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Incidence of dyspnea adverse events (%)</td>
              <td>13.8</td>
              <td>7.8</td>
              <td> &lt;0.001 </td>
            </tr>
            <tr>
              <td>Patients who discontinued treatment due to dyspnea (%)</td>
              <td>0.9</td>
              <td>0.1</td>
              <td> &lt;0.001 </td>
            </tr>
          </tbody>
        </table>
      </div>
      <!-- Table 2 -->
      <div class="post-table post-table-2">
        <table class="f-d-16 f-m-28">
          <thead>
            <tr>
              <td></td>
              <td>Clopidogrel</td>
              <td>Presugrel</td>
              <td>Ticagrelor</td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Drag class</td>
              <td>Thienopyridine</td>
              <td>Thienopyridine</td>
              <td>Cyclopentyl-triazolopyrimidine</td>
            </tr>
            <tr>
              <td>Reversibility</td>
              <td>Irreversible</td>
              <td>Irreversible</td>
              <td>Reversible</td>
            </tr>
            <tr>
              <td>Bioactivatoin</td>
              <td>Yes (pro-drug,CYP dependent, 2 steps)</td>
              <td>Yes (pro-drug,CYP dependent, 1 steps)</td>
              <td>No</td>
            </tr>
            <tr>
              <td>(Pretreatment) - Dose</td>
              <td>600 mg LD, 75 mg MD</td>
              <td>60 mg LD, 10 (5) mg MD</td>
              <td>180 mg LD, 2 x 90 (60) mg MD</td>
            </tr>
            <tr>
              <td>Onset of effect</td>
              <td>Delayed: 2-6 h</td>
              <td>Rapid: 0.5-4 h</td>
              <td>Rapid: 0.5-2 h</td>
            </tr>
            <tr>
              <td>Onset of effect</td>
              <td>3-10 days</td>
              <td>5-10 days</td>
              <td>3-4 days</td>
            </tr>
            <tr>
              <td>Delay to surgery</td>
              <td>5 days</td>
              <td>7 days</td>
              <td>5 days</td>
            </tr>
            <tr>
              <td>Kidney failure</td>
              <td>No dose adjusment</td>
              <td>No dose adjusment</td>
              <td>No dose adjusment</td>
            </tr>
            <tr>
              <td>Dialysis or CrCl &lt;15 mL/min</td>
              <td>Limited data</td>
              <td>Limited data</td>
              <td>Limited data</td>
            </tr>
          </tbody>
        </table>
      </div>
      <!-- Table 3 -->
      <div class="post-table post-table-3">
        <table class="f-d-16 f-m-28">
          <thead>
            <tr>
              <td>Recommendations</td>
              <td>Class</td>
              <td>Level</td>
            </tr>
            <tr>
              <td>Antiplatelet treatment</td>
              <td></td>
              <td></td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Aspirin is recommended for all patients without contraindications at an initial oral LD of 150-300 mg (or 75-250 mg i.v.), and at a MD of 75-100 mg o.d for long term treatment</td>
              <td>l</td>
              <td>A</td>
            </tr>
            <tr>
              <td>A P2Y receptor inhibitor is recommended in addition to aspirin, and maintained over 12 months unless there are contraindications or an excessive risk of  bleeding. Options are:</td>
              <td>l</td>
              <td>A</td>
            </tr>
            <tr>
              <td>• Prasugrel in P2Y receptor inhibitor-naïve patients proceeding to PCI (60 mg LD, 10 mg/d, 10 mg/d as standard dose. 5 mg/d for patients aged ≥ 75 years or with body weight <60 kg)</td>
              <td>l</td>
              <td>B</td>
            </tr>
            <tr>
              <td>• Ticagrelor irrespective of the planned treatment strategy (invasive or conservative) (180 mg LD, 90 mg b.i.d).</td>
              <td>l</td>
              <td>B</td>
            </tr>
            <tr>
              <td>• Clopidogrel (300-600 mg LD, 75 mg daily dose), one when prasugrel or ticagrelor are not available, cannot be tolerated, or are contraindicated.</td>
              <td>l</td>
              <td>C</td>
            </tr>
            <tr>
              <td>Prasugrel should be considered in preference to ticagrelor for NSTE-ACS patients who proceed to PCI.</td>
              <td>lla</td>
              <td>B</td>
            </tr>
            <tr>
              <td>GP llb/lla antagonists should be considered for bail-out if there is evidence of no reflow or a thrombotic complication.</td>
              <td>lla</td>
              <td>C</td>
            </tr>
            <tr>
              <td>Cangrelor may be considered in P2Y receptor inhibitor-naïve patient undergoing PCI.</td>
              <td>llb</td>
              <td>A</td>
            </tr>
            <tr>
              <td>Pre-treatment with a P2Y receptor inhibitor may be considered in patients with NSTE-ACE who are not planned to undergo an early invasive strategy and do not have an HBR.</td>
              <td>llb</td>
              <td>C</td>
            </tr>
            <tr>
              <td>Treatment with GP llb/lla antagonists in patients in whom coronary anatomy is not known is not recommended.</td>
              <td>lll</td>
              <td>A</td>
            </tr>
            <tr>
              <td>it is not recommended to administer routine pre-treatment with a P2Y receptor inhibitor in patients in whom coronary anatomy is not known and an early invasive management is planned.</td>
              <td>lll</td>
              <td>A</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>

  <!-- Post Cards -->
  <div class="post-cards">
    <div class="container">
      <div class="swiper">
        <div class="swiper-wrapper">
          <!-- Slide -->
          <div class="swiper-slide">
            <div>
              <div class="img">
                <img src="img/post/post-card-1.jpg" alt="brilinta-img">
              </div>
              <div class="text">
                <h3 class="f-d-16 f-m-16 semi-bold">PLATO</h3>
                <p class="f-d-16 f-m-16">
                  Wallentin L et al. NEJM​
                  <br>
                  Ticagrelor versus Clopidogrel in patients with Acute coronary syndromes​
                </p>
                <a href="#" class="link f-d-16 f-m-20">READ MORE <img src="img/icons/arrow-right-white.svg"
                    alt="brilinta-img"></a>
              </div>
            </div>
          </div>
          <!-- Slide -->
          <div class="swiper-slide">
            <div>
              <div class="img">
                <img src="img/post/post-card-2.jpg" alt="brilinta-img">
              </div>
              <div class="text">
                <h3 class="f-d-16 f-m-16 semi-bold">NSTE-ACS in PLATO​</h3>
                <p class="f-d-16 f-m-16">
                  Lindholm D et al. EHJ​
                  <br>
                  Ticagrelor vs clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without
                  revascularization: results from the PLATO
                </p>
                <a href="#" class="link f-d-16 f-m-20">READ MORE <img src="img/icons/arrow-right-white.svg"
                    alt="brilinta-img"></a>
              </div>
            </div>
          </div>
          <!-- Slide -->
          <div class="swiper-slide">
            <div>
              <div class="img">
                <img src="img/post/post-card-3.jpg" alt="brilinta-img">
              </div>
              <div class="text">
                <h3 class="f-d-16 f-m-16 semi-bold">PLATO SAFETY​</h3>
                <p class="f-d-16 f-m-16">
                  Becker RC et al. EHJ​
                  <br>
                  Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet
                  inhibition and patient Outcomes (PLATO) trial​​
                </p>
                <a href="#" class="link f-d-16 f-m-20">READ MORE <img src="img/icons/arrow-right-white.svg"
                    alt="brilinta-img"></a>
              </div>
            </div>
          </div>
        </div>
        <div class="swiper-pagination"></div>
      </div>
    </div>
  </div>

  <!-- Post Links -->
  <div class="post-links">
    <div class="container">
      <h2 class="f-d-22 f-m-30 text-orange">Brilinta is the only P2y12 inhibitor that reduces CV Death
      </h2>
      <div class="btns">
        <a href="#" class="popup-toggler btn btn-primary" data-popup="#post-popup">PLATO study design <img
            src="img/icons/arrow-right-white.svg" alt="brilinta-img"></a>
        <a href="#" class="popup-toggler btn btn-primary" data-popup="#post-popup">Additional clinical trials​ <img
            src="img/icons/arrow-right-white.svg" alt="brilinta-img"></a>
      </div>
      <div class="social">
        <ul>
          <li>
            <a href="#"><img src="img/icons/f.svg" alt="brilinta-img"></a>
          </li>
          <li>
            <a href="#"><img src="img/icons/in.svg" alt="brilinta-img"></a>
          </li>
          <li>
            <a href="#"><img src="img/icons/tw.svg" alt="brilinta-img"></a>
          </li>
        </ul>
      </div>
    </div>
  </div>

  <!-- Category Bottom -->
  <div class="category">
    <div class="bottom">
      <div class="container">
        <h2 class="f-d-30 d-desktop text-center text-purple">See More Articles</h2>
        <div class="swiper">
          <div class="swiper-wrapper">
            <!-- Slide -->
            <div class="swiper-slide">
              <div>
                <div class="img">
                  <img src="img/category/img-1.jpg" alt="brilinta">
                </div>
                <div class="text">
                  <h3 class="f-d-20 f-m-25">presentation about Brilinta for ACS patients</h3>
                  <a href="#" class="link f-d-16 f-m-35 medium">DOWNLOAD <img src="img/icons/arrow-right-white.svg"
                      alt="brilinta-img"></a>
                </div>
              </div>
            </div>
            <!-- Slide -->
            <div class="swiper-slide">
              <div>
                <div class="img">
                  <img src="img/category/img-2.jpg" alt="brilinta">
                </div>
                <div class="text">
                  <h3 class="f-d-20 f-m-25">'להאזנה לפודקאסט של פרופ

                    ACS סער מינחה על טיפול בחולי

                    בגיל השלישי</h3>
                  <a href="#" class="link f-d-16 f-m-35 medium">LISTEN NOW <img src="img/icons/arrow-right-white.svg"
                      alt="brilinta-img"></a>
                </div>
              </div>
            </div>
            <!-- Slide -->
            <div class="swiper-slide">
              <div>
                <div class="img">
                  <img src="img/category/img-3.jpg" alt="brilinta">
                </div>
                <div class="text">
                  <h3 class="f-d-20 f-m-25"> לצפייה בהרצאתו של פרופ' מטצקי
                    על הטיפול באוכלוסיות מיוחדות
                    ACSב</h3>
                  <a href="#" class="link f-d-16 f-m-35 medium">WATCH NOW <img src="img/icons/arrow-right-white.svg"
                      alt="brilinta-img"></a>
                </div>
              </div>
            </div>
            <!-- Slide -->
            <div class="swiper-slide">
              <div>
                <div class="img">
                  <img src="img/category/img-4.jpg" alt="brilinta">
                </div>
                <div class="text">
                  <h3 class="f-d-16 f-m-25">
                    Professor James interview about the findings and implications of the PRECLUDE study :
                    <br>
                    Culprit and non –culprit recurrent MI
                    Analysis from SWEDHEART registry
                  </h3>
                  <a href="#" class="link f-d-16 f-m-35 medium">WATCH NOW <img src="img/icons/arrow-right-white.svg"
                      alt="brilinta-img"></a>
                </div>
              </div>
            </div>
          </div>
          <div class="swiper-pagination d-mobile"></div>
        </div>
      </div>
    </div>
  </div>

  <!-- Home Prescription -->
  <div class="home-prescription">
    <div class="img">
      <img src="img/home/img-3.jpg" alt="brilinta-img">
    </div>
    <div class="text">
      <div class="text-content">
        <!-- Tabs -->
        <div class="tabs">
          <!-- Tab Navigation -->
          <div class="tab-navigation">
            <ul class="f-d-20 f-m-27 bold">
              <li class="tab-btn active" data-tab="#tab1">
                <a href="#">התוויה</a>
              </li>
              <li class="tab-btn" data-tab="#tab2">
                <a href="#">התווית נגד (קונטרהאינדיקציה)</a>
              </li>
            </ul>
          </div>
          <!-- Tab Content -->
          <div class="tab-content">
            <ul>
              <li class="tab-panel active" id="tab1">
                <h3 class="f-d-30 f-m-30">התוויה</h3>
                <p class="f-d-18 f-m-25"> ברילינטה בשילוב עם חומצה אצטיל–סליצילית (אספירין) , מיועדת
                  למניעת אירועים אתרותרומבוטיים בחולים מבוגרים עם</p>
                <ul class="f-d-18 f-m-25">
                  <li> או (ACS) תסמונת כלילית חדה</li>
                  <li> וסיכון גבוה לפתח ארוע (MI) היסטוריה של אוטם שריר הלב
                    אתרותרומבוטי</li>
                </ul>
                <p class="f-d-18 f-m-25">
                  מגבלות שימוש: 90 מ"ג פעמיים ביום בשנה הראשונה לאחר ארוע
                  (ACS)כלילי חד
                  <br>
                  ולאחר מכן 60 מ"כ למשך שנתיים נוספות
                </p>
                <p class="lined f-d-16 f-m-22">טרם יש לעיין בעלון לרופא <a href="#">מתן מרשם</a> כפי שאושר ע"י משרד
                  הבריאות</p>
              </li>
              <li class="tab-panel" id="tab2">
                <h3 class="f-d-30 f-m-30">התוויה</h3>
                <p class="f-d-18 f-m-25"> ברילינטה בשילוב עם חומצה אצטיל–סליצילית (אספירין) , מיועדת
                  למניעת אירועים אתרותרומבוטיים בחולים מבוגרים עם</p>
                <ul class="f-d-18 f-m-25">
                  <li> או (ACS) תסמונת כלילית חדה</li>
                  <li> וסיכון גבוה לפתח ארוע (MI) היסטוריה של אוטם שריר הלב
                    אתרותרומבוטי</li>
                </ul>
                <p class="f-d-18 f-m-25">
                  מגבלות שימוש: 90 מ"ג פעמיים ביום בשנה הראשונה לאחר ארוע
                  (ACS)כלילי חד
                  <br>
                  ולאחר מכן 60 מ"כ למשך שנתיים נוספות
                </p>
                <p class="lined f-d-16 f-m-22">טרם יש לעיין בעלון לרופא <a href="#">מתן מרשם</a> כפי שאושר ע"י משרד
                  הבריאות</p>
              </li>
            </ul>
          </div>
        </div>
      </div>
    </div>
  </div>

  <!-- Footer -->
  <footer class="footer">
    <div class="footer-top">
      <div class="container">
        <p class="f-d-16 f-m-22">
          References:
          <br>
          ‏1. wallentin l et al; for the plato investigators. ticagrelor versus clopidogrel in patients with acute
          coronary syndromes. n engl j med. 2009;361(11):1045-1057.and supplementary appendix
        </p>
        <ul class="f-d-16 f-m-25 medium">
          <li>
            <a href="#">תנאי שימוש</a>
          </li>
          <li>
            <a href="#">צור קשר</a>
          </li>
          <li>
            <a href="#">מדיניות פרטיות</a>
          </li>
          <li>
            <a href="#">מדיניות COOKIES</a>
          </li>
        </ul>
      </div>
    </div>
    <div class="footer-bottom d-mobile">
      <div class="container">
        <ul>
          <li>
            <a href="#"><img src="img/global/logo-2-gray-bg.jpg" alt="brilinta-img"></a>
          </li>
          <li>
            <a href="#"><img src="img/global/logo-gray-bg.jpg" alt="brilinta-img"></a>
          </li>
        </ul>
      </div>
    </div>
  </footer>

  <!-- Popup -->
  <div class="popup" id="post-popup">
    <!-- Backdrop -->
    <div class="popup-backdrop"></div>
    <!-- Content -->
    <div class="popup-content">
      <!-- Close -->
      <a href="#" class="popup-close">
        <img src="img/icons/close.svg" alt="alram-icon">
      </a>
      <!-- Body -->
      <div class="popup-body">
        <h2 class="f-d-22 f-m-34">PLATO trial design​</h2>
        <div class="row">
          <!-- Column -->
          <div class="col">
            <p class="f-d-16 f-m-30">n=18,624 patients with ACS (UA, NSTEMI or STEMI) randomized within 24 hours of
              symptom onset to BRILINTA or clopidogrel</p>
            <div class="box">
              <div class="bg-orange">
                <p class="f-d-16 f-m-30">BRILINTA 90mg (n=9,333)​</p>
              </div>
              <div class="bg-orange-light">
                <p class="f-d-16 f-m-30">
                  180mg loading dose​
                  <br> Followed by 90mg bid + ASA 75-100mg daily
                  ​​</p>
              </div>
            </div>
            <div class="bg-gray-light">
              <p class="f-d-16 f-m-30">
                Primary efficacy endpoint:
                ​​</p>
            </div>
            <p class="f-d-16 f-m-30">
              Composite of CV death, MI (excluding silent MI) or stroke
              ​​</p>
            <div class="bg-gray-light">
              <p class="f-d-16 f-m-30">
                Secondary endpoints:​
                ​​</p>
            </div>
            <ul class="f-d-16 f-m-30">
              <li>
                CV death + MI + stroke in patients intended for invasive management​
              </li>
              <li>
                All-cause-death + MI + stroke​
              </li>
              <li>
                CV death + MI + stroke + severe recurrent cardiac ischemia + recurrent cardiac ischemia + transient
                ischemic attack + other arterial thrombotic events​
              </li>
              <li>
                CV death alone/MI alone/stroke alone/all-cause-death alone
              </li>
            </ul>
          </div>
          <!-- Column -->
          <div class="col">
            <p class="f-d-16 f-m-30">
              <span class="bold">Initial treatment approaches​</span>
              <br>
              28% planned non-invasive management (n=5,216) 
              <br>72% planned invasive management (n=13,408)​
            </p>
            <div class="box">
              <div class="bg-purple">
                <p class="f-d-16 f-m-30">Clopidogrel 90mg (n=9,291)​​</p>
              </div>
              <div class="bg-purple-light">
                <p class="f-d-16 f-m-30">
                  300-600mg loading dose*​
                  <br>Followed by 75mg daily + ASA 75-100mg daily​
                  ​​</p>
              </div>
            </div>
            <div class="bg-gray-light">
              <p class="f-d-16 f-m-30">
                Primary safety endpoint:
                ​​</p>
            </div>
            <p class="f-d-16 f-m-30">
              Total PLATO major bleeding
              ​​</p>
            <div class="bg-gray-light">
              <p class="f-d-16 f-m-30">
                &nbsp;
                ​​</p>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>

  <!-- Script (Vendor) -->
  <script src="js/swiper-bundle.min.js"></script>
  <script src="js/gsap.min.js"></script>
  <script src="js/elevate-framework.js"></script>

  <!-- Script -->
  <script src="js/app.js"></script>

</body>

</html>